IRLAB Therapeutics AB Class A (0GFH) Stock Statistics & Valuation Metrics

IRLAB Therapeutics AB Class A has a market cap or net worth of kr175.47M. The enterprise value is kr83.31M.

IRLAB Therapeutics AB Class A has 141,430,440 shares outstanding. The number of shares has decreased by -2.65% in one year.

IRLAB Therapeutics AB Class A’s return on equity (ROE) is -3.58 and return on invested capital (ROIC) is -152.21%.

The current PE Ratio of IRLAB Therapeutics AB Class A is ―. IRLAB Therapeutics AB Class A’s PEG ratio is -0.48.

In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 57.46M and earned -110.01M in profits. Earnings per share was -1.64.

In the last 12 months, operating cash flow was -90.23M and capital expenditures 0.00, giving a free cash flow of -90.23M billion.

IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―

IRLAB Therapeutics AB Class A upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 67.98%

In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.

IRLAB Therapeutics AB Class A EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -1.45.

IRLAB Therapeutics AB Class A has kr50.79M in cash and marketable securities with kr27.08M in debt, giving a net cash position of kr23.70M billion.

Gross margin is -42.97%, with operating margin of -160.71%, and net profit margin of -191.45%.

The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―